Payment overview · 2025
General Payments
$514.47
28 reported records · 11 companies
Healthcare provider profile · identity verified
Charles A Kergosien, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKHAVEN, MS · NPI 1619087541
Verified facts
What the public records show
CMS Open Payments records show Charles A Kergosien, M.D. received $514.47 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.82 | 21.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.44 | 18.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.93 | 15.9% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $54.62 | 10.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.52 | 9.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $33.08 | 6.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.15 | 6.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.89 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.44 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.89 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.69 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $514.47 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $92.89 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $63.41 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.08 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $54.62 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.36 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.52 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.92 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $33.08 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.15 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.15 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 832 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 706 | 163 |
| Metformin Hcl Er | Metformin Hcl | 541 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 522 | 103 |
| Duloxetine Hcl | Duloxetine Hcl | 478 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 452 | 107 |
| Irbesartan | Irbesartan | 444 | 83 |
| Losartan Potassium | Losartan Potassium | 442 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 431 | 94 |
| Lisinopril | Lisinopril | 369 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 91 |
| Gabapentin | Gabapentin | 362 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 346 | 80 |
| Omeprazole | Omeprazole | 335 | 80 |
| Potassium Chloride | Potassium Chloride | 228 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 226 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 216 | 35 |
| Furosemide | Furosemide | 191 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 180 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 34 |
| Meloxicam | Meloxicam | 155 | 52 |
| Trazodone Hcl | Trazodone Hcl | 149 | 37 |
| Metformin Hcl | Metformin Hcl | 148 | 35 |
| Eliquis | Apixaban | 145 | 25 |
| Allopurinol | Allopurinol | 144 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 34 |
| Valsartan | Valsartan | 142 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 27 |
| Sertraline Hcl | Sertraline Hcl | 137 | 35 |
| Carvedilol | Carvedilol | 134 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 28 |
| Glimepiride | Glimepiride | 119 | 27 |
| Simvastatin | Simvastatin | 109 | 22 |
| Lovastatin | Lovastatin | 107 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 19 |
| Ozempic | Semaglutide | 94 | 21 |
| Famotidine | Famotidine | 90 | 25 |
| Ezetimibe | Ezetimibe | 86 | 28 |
| Spironolactone | Spironolactone | 80 | 20 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 79 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 12 |
| Alprazolam | Alprazolam | 72 | 12 |
| Januvia | Sitagliptin Phosphate | 72 | 11 |
| Montelukast Sodium | Montelukast Sodium | 72 | 21 |
| Synthroid | Levothyroxine Sodium | 71 | 15 |
| Atenolol | Atenolol | 69 | 13 |
| Celecoxib | Celecoxib | 66 | 17 |
| Bupropion Xl | Bupropion Hcl | 63 | 17 |
| Donepezil Hcl | Donepezil Hcl | 63 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 15 |
| Jardiance | Empagliflozin | 58 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 16 |
| Buspirone Hcl | Buspirone Hcl | 53 | 14 |
| Farxiga | Dapagliflozin Propanediol | 51 | 13 |
| Eszopiclone | Eszopiclone | 49 | suppressed |
| Mupirocin | Mupirocin | 49 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 14 |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 12 |
| Ramipril | Ramipril | 47 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 47 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 14 |
| Mirtazapine | Mirtazapine | 45 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 12 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Temazepam | Temazepam | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 27 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 32 |
| Baclofen | Baclofen | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 23 |
| Naproxen | Naproxen | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | 11 |
| Prednisone | Prednisone | 32 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 17 |
| Fluconazole | Fluconazole | 27 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Zaleplon | Zaleplon | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Minoxidil | Minoxidil | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $514.47 · 28 records | Novo Nordisk Inc | EVENITY, FARXIGA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error